Off-topic for aiqbench
This story was gathered from a source we follow but falls outside AI and quantum coverage, so there is no aiqbench take for it.
CITIC Securities: China's Innovative Drugs Continue to Break Through, with Competition and Differentiation Coexisting
36Kr reports that according to a CITIC Securities research report, at the 2026 European Society for Medical Oncology (ESMO) conference, Chinese innovative drugs are making comprehensive advances in multi-tumor areas, with numerous projects moving from early exploration into Phase III clinical trials or BLA/NDA stages. Domestic pharmaceutical companies have established a multi-front development pattern in tracks such as IO bispecific antibodies and multispecific antibodies, ADCs, and small-molecule targeted therapies, achieving positive endpoints in multiple Phase III trials. This continuous generation of internationally competitive clinical data marks the transition of China's innovative drug R&D from following innovation to source innovation and global leadership, shifting the industry logic from 'fast-follow' to a parallel stage of 'first-in-class' and 'best-in-class'.
Read the full article at 36KrRelated coverage
[AINews] LLMs can read & write neural network weights: "Weight Space Programming" cuts Autoresearch out of the RSI loop
Latent Space · Nov 3, 2026
The five phases of enterprise AI maturity, Part 2: Integrating AI and the AI-native enterprise
Cohere · May 13, 2026
Reinforcement Learning in High-Energy Physics: A Survey from Accelerator Control to Theory Exploration
arXiv · Nov 3, 2026
A Penalty Approach for Differentiation Through Black-Box Quadratic Programming Solvers
arXiv · Jun 16, 2026